We constructed predictive models and clinical nomograms to first differentiate HER2-positive from HER2-negative breast cancer, and then to distinguish the clinically critical HER2-low from HER2-zero subcategories within the HER2-negative group. This evidence concerns the gene ERBB2 and breast cancer.